VivoSeq
Oncology

Prostate Neoplasms

3

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Prostate Neoplasms is an early-stage landscape with 3 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 23

18f-Dcfpyl

University of Wisconsin, Madison

18f-Fdg

National Cancer Institute (NCI)

PSMA-11

National Cancer Institute (NCI)

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Radiopharmaceutical150%

Modality classified for 67% of 3 pipeline programs.

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03181867·360 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)